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 This RCT at 18-month follow-up found that ISTDP showed sustained treatment gains for TRD. 
 At 18 months follow-up 40% of ISTDP patients were in remission from depression. 
 Health economic analysis suggests that ISTDP is a cost-effective treatment for TRD compared to 
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Depressed patients with chronic and complex health issues commonly relapse; therefore, examining longer-
term outcomes is an important consideration. For treatment resistant depression (TRD), the post-treatment 
efficacy of time-limited Intensive Short-Term Dynamic Psychotherapy (ISTDP) has been demonstrated but 
longer-term outcomes and cost-effectiveness are unclear.  
Method 
In this superiority trial, 60 patients referred to Community Mental Health Teams (CMHT) were randomised 
to 2 groups (ISTDP=30 and CMHT=30). The primary outcome was Hamilton Depression Rating scale 
(HAM-D) scores at 18 months. Secondary outcomes included Patient Health Questionnaire (PHQ-9) 
depression scores and dichotomous measure remission. A health economic evaluation examined mental 
health costs with quality-adjusted life years (QALYs).  
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Results 
Statistically significant treatment differences in depression previously found at 6 months favouring ISTDP 
were maintained at 18-month follow-up. Group differences in depression were in the moderate to large range 
on both the observer rated (Cohen’s d = .64) and self-report measures (Cohen’s d = .70). At 18 months 
follow-up the remission rate in ISTDP patients was 40.0%, and 23.4% had discontinued antidepressants.  
Health economic analysis suggests that ISTDP was more cost-effective than CMHT at 18 months. 
Probabilistic analysis suggests that there is a 64.5% probability of ISTDP being cost-effective at a 
willingness to pay for a QALY of $25,000 compared to CMHT at 18 months.  
Limitations 
Replication of these findings is necessary in larger samples and future cost analyses should also consider 
indirect costs.  
Conclusions  
ISTDP demonstrates long-term efficacy and cost-effectiveness in TRD. 











 Depression is amongst the largest single causes of disability worldwide, and the disease burden of 
depression is on the rise globally (Murray and Lopez, 1997; WHO, 2013). Antidepressant treatment is 
considered a first line agent for major depression. However, up to half of patients do not show a satisfactory 
response (Kubitz et al., 2013). With every failed treatment the patient’s long-term prognosis deteriorates 
(Rush et al., 2006). Where adequate treatment dose and duration were applied, such cases are termed 
treatment resistant depression (TRD). A more specific indication for degree of treatment resistance may be 
based upon the number and type of prior antidepressant medication failures (Fava, 2003) and psychotherapy 
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treatments that did not lead to symptom remission. 
 A 2011 review of psychotherapy treatment for TRD found only 6 trials (Trivedi et al., 2011). 
Subsequent randomised controlled trials (RCTs) have reported mixed findings (Eisendrath et al., 2016; 
Fonagy et al., 2015; Souza et al., 2016; Wiles et al., 2013). We recently reported an RCT showing that 
Intensive Short-Term Dynamic Psychotherapy (ISTDP) is efficacious in the treatment of TRD (Town et al., 
2017). ISTDP showed statistically significant improvements in depressive symptoms, in the moderate to 
large range, compared to routine treatment by secondary care Community Mental Health Teams (CMHTs): 
after 6 months patients in the ISTDP group were more likely to achieve complete remission (36.0% vs. 
3.7%) or partial remission (48.0% vs. 18.5%). 
 Alongside the paucity of empirical support for psychotherapies with TRD, there is a shortage of 
information on longer-term outcomes, though relapse and reoccurrence rates are typically high. At 24 
months after treatment for TRD, patients randomly allocated to long-term psychoanalytic psychotherapy 
demonstrated sustained benefit (Fonagy et al., 2015). Cognitive behaviour therapy (CBT) also showed 
significant advantages at a 40-month follow-up in TRD (Wiles et al., 2016). Complete remission rates in 
these TRD RCTs at long-term follow-up for the psychotherapy treatments were just 14.9% and 28% 
respectively.  
 In this study, we examined whether the effects of ISTDP are sustained 12 months after treatment, 
compared with patients receiving ongoing treatment at CMHTs. In our earlier study, short-term outcomes in 
the ISTDP group revealed significant improvement in depressive symptoms, declining from severe at 
baseline to mild/moderate at end of treatment. Meta-analyses of long-term outcomes of Short-Term 
Psychodynamic Psychotherapy (STPP) report sustained treatment effects in follow-up, and indicate further 
small improvement (Driessen et al., 2015). With complex, refractory, often chronic depression, evidence 
from previous trials suggests that further post-treatment gains in TRD are unlikely. We therefore 
hypothesized that the decrease in ISTDP patients’ depression during the course of treatment would flatten 
off and stabilize after treatment ended, but the treatment gains observed would remain greater in patients 
who received ISTDP compared to CMHT treatment. Finally, we examined cost-effectiveness of ISTDP 
versus CMHT treatment. 
 
2. Methods 
2.1. Study Design 
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 This superiority trial used a single blind randomised parallel group design to examine the efficacy of 
ISTDP versus secondary care treatment as usual (TAU) provided by CMHTs, for depressed patients who 
were non-remitting following at least one antidepressant treatment course. The original study design and 
power calculation, that resulted in the recruitment of 60 participants, has previously been described (Town et 
al., 2017).  
 The primary cost-effectiveness analysis (CEA) assesses the value for money of ISTDP versus CMHT 
in terms of the incremental cost required to gain incremental improvement in quality adjusted life years 
(QALYs) over the 18-month study period. A secondary CEA was conducted to assess the value for money 
of intensive ISTDP versus CMHT in terms of the incremental cost required to gain incremental improvement 
in the HAM-D over the 18-month study period. In both the primary and secondary analyses, cost-
effectiveness was assessed using incremental cost-effectiveness ratios (ICERs). The present study takes the 
cost perspective of the mental health payer and measures cost in 2017 Canadian Dollars. For a detailed 
description of the CEA see the Online Appendix.  
 The study protocol was registered with ClinicalTrials.gov (ID: NCT01141426) and approved by the 
Nova Scotia Health Authority Research Ethics Board (NSHA-RS/2013-049). All participants provided 
written informed consent. 
 
2.2.Participant Eligibility and Recruitment  
 Between September 2012 and March 2015, 143 potential participants were referred to the study by 
clinicians from 4 secondary care outpatient CMHTs based in Halifax Regional Municipality, Nova Scotia, 
Canada. Patients eligible to be referred were outpatients, aged 18-65 years, with a primary diagnosis of 
major depressive disorder according to DSM-IV criteria. Patients met study criteria for TRD by having had 
at least one trial of antidepressants at the adequate recommended therapeutic dose; a current depressive 
episode duration of 6 or more weeks; inadequate response to treatment (assessed by 17-item HAM-D score  
16); not having started further medication or changed dose of existing medication in the previous 6 weeks; 
and not having received treatment in the previous 2 years at any of the 4 CMHTs. Of the 120 patients 
assessed, 60 did not meet inclusion criteria or declined participation, hence were excluded. The study’s 
CONSORT diagram is presented in Figure 1. 
 
2.3.Randomisation and Allocation 
฀฀฀฀฀฀฀฀฀
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 Research assistants, who remained blind throughout the randomisation and allocation process, 
conducted screening assessments and enrollment. At the end of enrollment, an administrator allocated 
patients to ISTDP or CMHT treatment in a 1:1 ratio. For purposes of randomisation a researcher external to 
the study team generated a permuted block randomisation sequence using a random number generator. 
 
2.4.Intervention Protocol 
2.4.1. Intensive Short-Term Dynamic Psychotherapy 
 The ISTDP treatment provided is discussed in detail in our earlier study (Town et al., 2017). ISTDP 
was delivered in a 20-session time-limited, individual format, and according to published recommendations 
(Abbass, 2015; Davanloo, 2000). The mean number of sessions completed was 16.1 (SD = 6.68) (Town et 
al., 2017). ISTDP therapists were licensed professionals with supervised experience practicing ISTDP (mean 
experience = 10.25 years, range = 4-20 years). Trained independent researchers established the integrity of 
the ISTDP intervention (Town et al., 2017) using the Comparative Psychotherapy Process Scale (CPPS) 
(Hilsenroth et al., 2005). 
 
2.4.2. Medication Management  
 A medication washout phase was not specified in the protocol prior to treatment allocation to avoid 
possible withdrawal and subsequent treatment effects. For participants receiving ISTDP it was requested that 
medication(s) remain stable. Participants’ general practitioners (GP) were contacted to monitor medication. 
Participants were advised to discuss medication with their GP. For participants receiving care at a CMHT, 
pharmacotherapy treatment strategies consisted of individualized regimes informed by Canadian-based 
clinical guidelines (Lam et al., 2009). 
 
2.4.3. Secondary Care Treatment at Community Mental Health Teams  
 At each CMHT site, treatment consisted of a multidisciplinary team including pharmacotherapy and 
clinical management, supportive or structured activities focused around symptom management and, in some 
cases, individual or group psychotherapy. Treatment was unregulated, thus facilitating a naturalistic 
assessment of standard secondary care treatment- except that the trial CMHT participants were not offered 
ISTDP. Patients receiving CMHT treatment could receive ongoing care beyond the 6-month assessment. 
Due to the range of interventions available, formal treatment integrity ratings were not conducted, but details 
on doses, duration, and approaches delivered were documented. In our previous study, we reported that in 
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the CMHT group during the initial 6-month study period, 29 participants (97%) received at least one session 
of talking therapy (mean number of sessions = 7.6, SD = 3.7). The one-to-one therapy delivered by CMHTs 
was primarily counseling (57%) or CBT (40%). In addition, 15 participants (50%) received group therapy 
within a structured 10-12 two-hour session CBT format. Participants receiving CMHT treatment were more 
likely to have pharmacotherapy increased or changed than those in the ISTDP group (53% vs. 10%).  
 
2.5. Outcome Measures  
 We conducted outcome assessments at study baseline, mid-treatment (pre-session 11), post-
treatment, and then 3, 6 and 12 months post-treatment in the ISTDP group. CMHT group patients followed 
an equivalent assessment schedule, specifically at the study baseline and then at 3, 6, 9, 12 and 18 months 
following enrolment. 
 
2.5.1. Primary Outcome 
 The primary measure of participants’ depressive symptomology was the observer-rated 17-item 
HAM-D (Hamilton, 1967). A research assistant was trained to use a standardized clinical interview to 
administer this structured rating system designed to assess depressive symptom severity (Bech et al., 2003). 
During training, 3 clinical interviews were rated by the evaluator and ratings compared with an expert’s 
ratings. Research assistants were blind to treatment condition. Patients were instructed to refrain from 
discussing their treatment during assessments. All interviews were videotaped to assess rating reliability. To 
prevent rater drift the evaluator met with an independent experienced evaluator (clinical psychologist) at 
regular intervals to review videotaped interviews. Twenty-six HAM-D assessments were independently 
rated by both evaluators. The average between-rater intraclass correlation coefficient, ICC (2,1), was 0.96.  
  
2.5.2. Secondary Outcomes 
 Our secondary depression outcome was the scale sum score from the 9-item patient-rated Patient 
Health Questionnaire (PHQ-9) (Kroenke and Spitzer, 2002). Additional secondary outcome measures 
included self-reported anxiety measured using the Generalized Anxiety Disorder scale (GAD-7) (Spitzer et 
al., 2006); psychological well-being rated with Clinical Outcomes in Routine Evaluation Outcome Measure 
(CORE-OM: overall score) (Barkham et al., 2005); interpersonal functioning via the Inventory of 
Interpersonal Problems (IIP-32: overall score) (Horowitz et al., 2000); and somatic symptoms were 
measured (Patient Health Questionnaire PHQ-15) (Kroenke et al., 2001).  
฀฀฀฀฀฀฀฀฀
Downloaded for Anonymous User (n/a) at Nova Scotia Health Authority from ClinicalKey.com by Elsevier on May 11, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
 8 
 For a series of supplementary descriptive analyses, we converted the sum score versions of the 
HAM-D and PHQ-9 to binary outcomes representing full and partial remission. ‘Being in remission’ was 
defined as achieving a HAM-D score  7; ‘response’, by the HAM-D score having reduced by ≥ 50% from 
baseline. For the PHQ-9 measure, remission was defined as achieving a scale sum of  4; ‘response’ by a 
reduction of ≥ 50%. 
  
2.5.3. Measuring Cost Effectiveness 
 The CEA used QALYs calculated with the SF-6D scoring algorithm using data collected with the 
SF-12 (Ware et al., 1996); and also HAM-D scores. Costs included in the analysis are: interventional costs 
(ISTDP and CMHT); inpatient costs; outpatient costs; physician fees; out-of-pocket costs; and medications 
related to mental health. Service utilization was identified using a combination of medical chart review, 
patient self-report using the Trimbos and Institute of Medical technology Assessment Cost Questionnaire for 
Psychiatry (TIC-P) (Hakkaart-van Roijen, 2002) at each follow-up period, and the study jurisdiction’s 
administrative database for physician billings. Data related to indirect time delivering ISTDP treatment, 
including preparation and supervision, was collected from study therapists. The costs described above were 
calculated by multiplying estimates of the unit prices by the number of times the corresponding service was 
used, with the exception of physician billings, which were obtained from a jurisdictional database. 
Additional costing information is provided in the Supplementary Appendix. 
 
2.6.Statistical Analyses 
Within psychotherapy research, models for longitudinal data have typically been restricted to linear change, 
i.e.,  
 
However, change rarely continues linearly in perpetuity.  Curvilinearity is sometimes modelled via adding a 
quadratic term to a linear model, i.e. 
 
but under this model our predicted value will still eventually accelerate towards plus or minus infinity as 
time increases.  
 
฀฀฀฀฀฀฀฀฀
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The most appropriate way to model decelerating change towards a limit or ‘asymptote’ is by a ‘true’ non-




where time is coded from the start of the study (i.e. time-point 1 is time = 0) and the parameters (regression 
coefficients) estimated represent the initial level (i.e. intercept) of depressive symptoms (init); the asymptote 
(asymp); and the shape of change (rate). This true non-linear function approach is recommended (Pinheiro 
and Bates, 2001; Singer and Willett, 2003) when the underpinning theoretical model involves convergence 
to a stable level, known as an ‘asymptote’, as opposed to continuous linear decrease or increase. We re-
parameterised this model to contain a parameter diff, where diff represented, and hence provided a test of the 
difference between the initial (time 1) value of the outcome and the asymptote (the level at which it had 







Given the multilevel nature of our data (six observations over time nested within patients, giving us non-
independence of observations), we treated the intercept (in the non-linear context, parameter init) as a 
random effect. For each outcome we first calculated an unconditional model (no predictors) to give baseline 
estimates for within- and between-subject variance. We then compared the non-linear exponential decay 
model outlined above with the more ubiquitous linear and quadratic models. Where the non-linear model 
was best, we added random effects, for diff and rate, with these variance term(s) retained if they enhanced 
model fit. Finally, we aimed to explain any variation in init, diff and/or rate by treatment group membership: 
if the extent and shape of change varied between patients, was this due to different treatment (i.e., ISTDP or 
CMHT) received?  
 Models were fitted using the linear and non-linear mixed effects packages (lme, nlme) in open-source 
statistical programming software R. In each model we included an autoregressive (AR1) random effect to 
฀฀฀฀฀฀฀฀฀
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account for the within-subject correlation structure of repeated measures data. Time was coded in units of ‘3 
months from the start of the study’ (time point 1 = 0, time point 2 = 1, etc). Non-linear models were 
compared with the linear options by the (smaller is better) Akaike and Bayesian Information Criteria (AIC 
and BIC). Non-linear models with differing random effects were compared using a chi-square difference 
test. The p < 0.05 level of statistical significance was used throughout.  
 
For each outcome we also calculated effect sizes (Cohen’s d) for change between time points 1 and 6, by 





 Differences between groups in non-discounted service use costs over the 18-month trial period were 
examined using t-tests and costs were log-transformed to account for skewness. 
 In the primary analysis, ISTDP was compared to CMHT using QALY’s and secondary analysis used 
HAM-D scores. We used multiple predictive imputation (MI) to address missing data for the SF-6D. 
Predictor variables included in the MI were those shown to be significantly correlated with quality of life: 
age, gender, marital status, employment status, education, and length of unemployment. We performed the 
analysis on 10 imputed datasets, and the results combined using Rubin’s rule (Rubin, 1987).  
 ICER in the reference case analysis were calculated using the difference in cost and difference in 
QALY between groups over the 18-month trial, discounted at 1.5%. A cost effectiveness acceptability curve 
(CEAC) illustrating the probability of the intervention being effective at different willingness-to-pay 
threshold values was produced. ICER in the secondary analysis were calculated using the difference in cost 
and the difference in improvement in HAM-D scores between groups over the 18-month trial. Cost data 
were discounted at 1.5% and HAM-D scores were not discounted.  
 Sensitivity analyses were performed to assess the results of CEA. Additional ICER were calculated 
using discount rates of 0% and 3%. Further sensitivity analyses were also conducted using QALY calculated 
using mean interpolation to address missing data instead of the MI approach.  Further sensitivity analysis is 
conducted removing high volume service users. A probabilistic analysis (PA) is also conducted for both the 
primary and secondary CEA. Additional details for and results of the sensitivity analyses are reported in the 
Online Appendix. 
฀฀฀฀฀฀฀฀฀
Downloaded for Anonymous User (n/a) at Nova Scotia Health Authority from ClinicalKey.com by Elsevier on May 11, 2020.




 Adverse events during the trial’s initial 6 months occurred in two participants in the CMHT group 
who reported increases in depressive symptoms (Town et al., 2017). In the 12 months follow-up, due to a 
deterioration in mental health, one participant from each treatment condition required mental health inpatient 
care. Neither patients’ decline in mental health was judged to be related to the study intervention.  
 
3. Results 
3.1. Sample Description  
 As reported within our previous study (Town et al., 2017), no significant differences were found in 
participant clinical characteristics between the treatment conditions. The majority of participants scored 
within the severe range on the HAM-D alongside comorbid mental health disorders and chronic physical 
illness; 96.7% had a comorbid Axis I disorder; 89.7% fulfilled criteria for Axis II personality disorder. The 
60 randomised participants were included in our primary ‘intention to treat’ analysis sample. Of the 30 
participants randomised to ISTDP, 2 dropped out of the study immediately after randomisation due to work 
commitments; 1 dropped out after 1 session, and 2 more dropped out after 8 sessions, again due to work 
commitments. In the CMHT group, all participants were seen for at least one appointment. Figure 1 
summarises participant flow through the study. 
 The aforementioned treatment drop-out was accompanied by a handful of non-completed measures at 
time points 1 to 3, and a larger degree of non-response at latter time points. Our primary intention to treat 
analysis included all available patient data. This final sample consisted of 279 responses from 60 
participants, with complete data at time-point 1 (baseline), 55 participants responding at time-point 2, 52 at 
time-point 3, 39 at time-point 4, and 37 at time-point 5 and 6. Thirty-six participants (17 receiving CMHT 
treatment, 19 receiving ISTDP) responded at all time points.  
 
3.2.Treatments Received 
 During the 12-month follow-up assessment period, data were collected on treatments received for 58 
of the randomised participants (ISTDP = 30; CMHT = 28). Table 1 summarises the treatment received 
within the experimental and comparison conditions. Participants in the CMHT group were more likely to 
receive talking therapy, participate in group CBT, and receive psychosocial interventions than those in the 
ISTDP group. Pharmacotherapy utilization was lower in the follow-up period for the ISTDP group: 
฀฀฀฀฀฀฀฀฀
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participants were less likely to receive antidepressants or have psychiatric medications changed and more 
likely to be medication free at 18 months. Across the study period there was a significant reduction in the 
total number of psychiatric medications prescribed in the ISTDP group but a significant increase in 
psychiatric medications prescribed within the CMHT group. 
 
3.3.Modelling Continuous Outcomes 
 Model comparisons and random effects estimates for HAM-D and PHQ-9 are given in the Online 
Appendix, with fixed coefficients from the final (best) model for each outcome presented in Table 2. 
Equivalent statistics for secondary outcomes (GAD-7, IIP-32, CORE-OM, and PHQ-15) are given in the 
Online Appendix.  
For all outcomes other than IIP (linear change), the exponential decay model outperformed linear or 
quadratic models. Estimated growth curves for outcomes modelled using an exponential decay model have 
converged very close to their asymptote after 3 time points, i.e. at the end of treatment, and offer a good fit 
to the sample means (see Figure 2). Basic effect sizes (Cohen’s d) for group differences at each time point 
are given for HAM-D and PHQ-9 in Table 3.  
 For the primary outcomes HAM-D and PHQ-9, adding a random effect for the difference parameter 
improved model fit (change in -2LL = 11.851, 1df, p < 0.05; change in -2LL = 8.552, 1df, p < 0.05, p < 0.05 
respectively), but there was no evidence for variation between subjects in the rate of symptom decrease.   
  Treatment group was unrelated to the initial (intercept) level of all outcomes (as would be expected 
given the randomised group allocation). Treatment group was, however, a significant predictor of the 
difference parameter for both HAM-D and PHQ-9. The ISTDP group reported a greater decrease in 
depressive symptoms from time 1 to the asymptote (B = 4.184, p < 0.05; B = 4.082, p < 0.05 respectively). 
Treatment group explained 9.5% of between-subject variance in the decrease for HAM-D, and 11.3% of 
variance in the decrease for PHQ-9. Treatment group was unrelated to the difference parameter for the other 
secondary outcomes. 
 These results support our primary hypothesis that ISTDP yields a greater improvement in patients’ 
depressive symptoms relative to CMHT treatment at the 18-month study period. More specifically, the 
degree of treatment gains observed after 6 months remained greater in patients who received ISTDP and 
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 The proportion of cases in full remission and showing response follow the pattern displayed by 
continuous versions of the measures, namely an improvement during treatment followed by stabilization in 
the 12 months follow-up.  Comparing the ISTDP group to CMHT, HAM-D full remission stabilizes at 
approximately 40% vs. 29%; response, at 50% vs. 41%. PHQ-9 full remission stabilizes at approximately 
30% vs. 25%; response, at 55% vs. 38%.  
 
3.5.Cost Effectiveness 
 Over the total 18 months of the trial, the log-transformed non-discounted total cost for the CMHT 
group was slightly lower than that for the ISTDP group, but the difference in between groups was not 
statistically significant. The mean difference in log- transformed costs was -0.04 (95% CI = -0.36 to 0.28, p 
= 0.81).  When using the raw rather than log-transformed scores, the direction of this difference was 
reversed: this is the result of several high-volume service users within the CMHT group.  
 Using total healthcare costs and QALYs as the measure of effect, the ISTDP group offered lower 
cost and higher quality of life (0.90 vs 0.87) at 18 months with a discount rate of 1.5% (See Table 4). 
Alternative discount rates of 0% and 3% did not substantially affect findings. In the secondary analysis, 
using total healthcare costs and HAM-D scores as the measure of effect, ISTDP was associated with lower 
cost and more improvement in HAM-D scores at 18 months using a discount rate of 1.5% (See Table 4). 
Alternative discount rates of 0% and 3% again did not substantially affect findings.  
 Overall, results of sensitivity analyses revealed similar findings. When high volume service users 
were removed from the dataset and replaced with the group average total cost over the 18 months of the trial, 
differences in total group costs remained non-significant. Furthermore, results were sensitive to methods of 
handling missing data. The MI approach in the reference case analysis yielded more treatment effect for 
ISTDP than a mean interpolation approach, though in both cases ISTDP was more effective.  
 
 Probabilistic analysis demonstrated ISTDP cost savings in 2.5% of PA iterations and improved 
QALY in 70.3% of PA iterations. For ISTDP, at a willingness to pay (WTP) of $25,000 per QALY, 64.5% 
of PA iterations were cost-effective and at a WTP of $50,000 per QALY, 67.3% of PA iterations were cost-
effective. In secondary analysis, ISTDP was cost savings in 2.5% of PA iterations and more effective in 
99.5% of PA iterations. For ISTDP, at a WTP of $100 for a 1-point improvement in HAM-D scores, 88.1% 
of PA iterations were cost-effective; at a WTP of $500 for a 1-point improvement in HAM-D scores, 98.3% 
of PA iterations were cost-effective. 
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4. Discussion 
 The Halifax Depression Study RCT examined the efficacy and cost-effectiveness of time-limited 
ISTDP for secondary care patients with TRD at short- and medium-term follow-up. We previously reported 
that in the short-term, ISTDP was superior to CMHT treatment. After 6 months treatment, improvements in 
depression scores for those receiving ISTDP were greater than for patients receiving CMHT treatment 
(Town et al., 2017). 
 At the 18-month follow-up assessment, the significant improvements in the ISTDP group post-
treatment had been maintained. The within group ISTDP effects sizes were in the large range (Cohen’s d: 
HAM-D = 1.80; PHQ-9 = 1.66). This study is the first RCT to demonstrate sustained effectiveness of an 
STPP for TRD at 18 months follow-up. Based on the trend of increased antidepressant prescribing in 
developed countries (Lubian et al., 2016; Olfson and Marcus, 2009) and no evidence of reduction in 
antidepressants following other evidence-based psychotherapies for TRD (Wiles et al., 2016), it is 
significant that a quarter of patients in the ISTDP group had stopped all medications at 18 months. This 
expands the consideration for psychotherapy approaches for this complex and refractory condition to include 
ISTDP. It remains that trained therapists are typically in short supply with long waiting lists. The current 
findings justify recommending investment in training of therapists in this brief treatment modality. 
 The numerical remission rates following ISTDP at 18 months (40%) are comparable to the largest 
remission rates at 12 months in other published RCTs for TRD (40% (Wiles et al., 2013); 37.5% (Eisendrath 
et al., 2016)). The remission rates at longer-term follow-up reported in previous trials for TRD are lower 
(28% at 46 months (Wiles et al., 2016); 14.9% at 42 months (Fonagy et al., 2015)) than those at 18 months 
following ISTDP. Based on the remission rates reported over time in the CoBALT study (Wiles et al., 2016), 
the effectiveness of CBT for TRD may decline over long-term follow-up. In residual depression, the effects 
of CBT in preventing relapse and recurrence were initially found to persist, but were lost at longer-term 
follow-up (Paykel et al., 2005). Although the Tavistock Depression Study found that decrease in depression 
scores continued after long-term psychoanalytic psychotherapy, 18 months post-treatment remission rates 
were ‘infrequent’ (Fonagy et al., 2015). It is unclear whether smaller treatment effects at long-term follow-
up based on the complex needs of people with TRD are to be expected. Future research needs to better 
understand if therapy could be optimised, extended or medically augmented to facilitate remission. 
 As predicted, we observed a significant difference in treatment efficacy between groups on 
depression - but not for secondary outcome measures. In this study, significant improvement from baseline 
to 18 months was seen in both treatments on symptoms of generalized anxiety, somatic symptoms and 
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general well-being. One possible explanation for small observed differences between groups on these 
secondary measures is that this time-limited format of ISTDP was designed specifically to focus on 
depressive symptoms, and it might have only had a non-specific effect in certain domains similar to that 
observed in the CMHT treatment. Within group changes on these measures were modest, suggesting that 
treatment for TRD can be optimised to achieve gains on these other measures.  
 We previously noted that the between-group difference in efficacy could be related to ISTDP 
participants receiving a greater treatment dosage (Town et al., 2017). However, during the 12-month follow-
up, participants in the CMHT group were more likely to receive psychiatric medication adjustments and talk 
therapy, such that the mean number of sessions per patient during the 18-month study duration was not 
significantly different between groups. Therefore, the number of sessions likely did not influence the 
efficacy findings; yet, it remains possible that treatment session frequency influenced therapeutic 
effectiveness (Cuijpers et al., 2013). While the effectiveness of the psychotherapy delivered in CMHTs 
could have been improved with weekly sessions, some evidence indicates talk psychotherapy for depression 
can be optimized with twice weekly sessions at the start of treatment (Bruijniks et al., 2020). The smaller 
between-groups effect sizes on depression measures reported here at the 6- and 18-month assessments, 
compared to those previously observed at post-treatment using linear modelling, may be a product of the 
more sophisticated non-linear exponential decay model utilised, which enables the modelling of convergence 
to an asymptote rather than the unrealistic assumption of continuous linear decrease in depression.  To avoid 
over-estimating treatment effects in longitudinal studies with multiple post-treatment measurements, 
psychotherapy researchers should consider this analytic approach for modelling the decreasing rates of 
change post-treatment.  
 Using non-linear modelling, the current results comparing time-limited ISTDP versus an active 
CMHT treatment providing an equivalent mean number of psychotherapy sessions plus medication 
treatment augmentation, showed an average difference between groups of 4.8 points on the HAM-D-17 
measure at 18 months follow-up favouring ISTDP. This difference is twice the mean antidepressant-placebo 
difference of 2 HAM-D points seen at the end of drug treatment (Cipriani et al., 2018). While it has been 
pointed out that reliance on subjective measures of outcomes in depression and statistically significant group 
differences have led to the over-estimation of antidepressant treatment effects (Hengartner and Plöderl, 
2018), we point to the 40% remission rate at 18 months post treatment in this study, in a sample with high 
rates of multi-morbidity and previous failed treatments, to indicate the clinical relevance of these findings. 
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 Healthcare costs associated with TRD are high (Fostick et al., 2010; Olchanski et al., 2013) and 
psychotherapy treatments are expensive. Findings suggest that ISTDP may be a cost-effective alternative to 
CMHT for secondary treatment of refractory depression. Findings suggest that ISTDP was associated with 
similar costs and superior effectiveness in both the primary and secondary analyses. PA in the primary 
analyses suggested that there was a 64.5% probability of ISTDP being cost-effective compared to CMHT at 
a WTP/QALY of $25,000.  
 The strengths of the Halifax study design, alongside its limitations, have been previously outlined 
(Town et al., 2017). In particular, including a proponent of CMHT delivered care within the study team 
would have reduced the likelihood of an allegiance effect (Luborsky et al., 1999) in this project. We 
considered this randomised controlled study a stringent test of the real-world effectiveness of a time-limited 
psychotherapy protocol compared to usual care delivered over 18 months by secondary care CMHTs. To our 
knowledge, it is the first to examine both longer-term outcomes and cost effectiveness of a STPP approach 
for TRD. The results of the clinical outcome data are limited by missing data at follow-up assessment. In the 
cost-effectiveness analyses, collection of participants’ health care service use data from provincial 
administrative databases and health records largely negated this issue, although this also meant analyses 
were limited to the available data. This economic evaluation is subject to several limitations. Notably, more 
rigorous costing would be of benefit in future study. The present study did not collect all overhead costs 
associated with treatments and as a result likely understates the cost associated with the models of care 
evaluated. As ISTDP appeared to use more services up front but CMHT appeared to use more services in the 
long-run, analysis using a longer time horizon would be of benefit. The present study also collected costs 
related to mental health services only. As depression may impact other areas of health and social care, 
broader categories of cost would be of interest in future study (McCrone et al., 2017). The study’s sample 
size was not chosen to inform the economic evaluation. Future study with larger sample size would be of 
value, specifically for analysing cost data which tends to be skewed. 
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 N   N    
Talking Therapy      
Any Talk Therapy (%) 10 (33.3)  21 (75.0) = 10.106 .001** 
     Mean Sessions (SD) 2.9 (6.1)  8.5 (7.7) t= 3.061 .003** 
1:1 Therapy (%) 9 (30.0)  20 (71.4) = 9.943 .002** 
1:1 Mean Sessions (SD) 2.3 (5.3)  6.1 (6.8) t= 2.401 .020* 
     ISTDP (%) 1 (3.3)  0 = 0.950 .330 
     CBT (%) 1 (3.3)  9 (32.1) = 8.424 .004** 
     Counselling (%) 7 (23.3)  9 (32.1) = 0.563 .453 
     Psychodynamic (%) 2 (6.7)  2 (7.1) = 0.005 .943 
Group CBT (%) 2 (6.7)  9 (32.1) = 6.116 .013* 
CBT Group Mean Sessions (SD) 0.6 (2.3)  2.9 (4.9) t= 2.269 .029* 
      
Other Interventions      
Psychosocial Intervention (%) 1 (3.3)  6 (21.4) = 4.469 .035* 
     Guided Self-help (%) 1 (3.3)  5 (17.9) = 4.603 .032* 
     Peer support group (%) 0  3 (10.7) = 3.390 .066 
     Meditation group (%) 0  2 (7.1) = 2.219 .136 
     Healthy living plans (%) 1 (3.3)  2 (7.1) = 0.429 .513 
A&E urgent care (%) 1 (3.3)  2 (7.1) = 0.429 .513 
Mental Health Day Hospital (%) 1 (3.3)  1 (3.6) = 0.002 .960 
Inpatient Admission (%) 1 (3.3)  1 (3.6) = 0.002 .960 
Psychiatry (%) 3 (10.0)  6 (21.4) = 1.443 .230 
      
Psychiatric Medications      
Antidepressants (%) 22 (73.3)  27 (96.4) = 5.893 .015* 
Anxiolytics (%) 9 (30.0)  13 (46.4) = 1.660 .198 
Antipsychotics (%) 1 (3.3)  7 (25.0) = 5.718 .017* 
Hypnotics (%) 4 (13.3)  6 (21.4) = 0.665 .415 
      
Medications added/changed (%) 7 (23.3)  15 (53.6) = 5.625 .018* 
Medications stopped/reduced (%) 9 (30.0)  4 (14.3) = 2.057 .152 
T6 N of medications (mean/SD) 1.3 (1.2)  2.4 (1.2) t = 3.683 .001** 
T6 Zero medications (%) 8 (26.7)  0  = 8.661 .003** 
 
Note: Statistical comparisons of differences between groups were conducted on proportions 
using the chi-square test and of means with Student t-tests. CBT- cognitive behaviour therapy; 
ISTDP- intensive short-term dynamic psychotherapy; CMHT- community mental health team 
*p < 0.05, **p < 0.01 
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Table 2: Estimated fixed effects coefficients (B) and 95% Confidence Intervals (CI) from exponential decay growth models 
with random initial value and change parameters, and study group as a predictor of variation in initial value and change 
 
  Outcome: HAM-D  Outcome: PHQ-9 
Model Parameter  B 95% CI  B 95% CI 
init.(Intercept)  24.212* (22.031, 26.394)  20.409* (18.462, 22.356) 
init.GROUP  -0.636 (-3.716, 2.443)  -1.168 (-3.919, 1.583) 
diff.(Intercept)  6.370* (3.484, 9.255)  5.938* (3.057, 8.818) 
diff.GROUP  4.184* (0.148, 8.220)  4.082* (0.151, 8.012) 
rate  1.233* (0.662, 1.804)  1.091* (0.570, 1.613) 
 
N = 279 observations from 60 individuals across 6 time points. 
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Time point ISTDP CMHT Pooled SD 
Mean 
Difference 
Cohen’s d 95% CI for Cohen’s d 
 mean† SD mean† SD    
HAM-D 1: Baseline 23.576 5.309 24.212 5.169 5.240 -0.636 -0.121 (-0.625, 0.388) 
 2: 3 months 16.099 8.088 19.700 7.833 7.966 -3.601 -0.452 (-0.980, 0.101) 
 3: 6 months  13.919 8.995 18.384 6.648 7.863 -4.465 -0.568 (-1.106, 0.002) 
 4: 9 months 13.284 7.358 18.000 8.514 7.879 -4.717 -0.599 (-1.228, 0.064) 
 5: 12 months 13.098 7.959 17.889 8.782 8.322 -4.790 -0.576 (-1.222, 0.103) 
6: 18 months 13.044 6.529 17.856 8.569 7.531 -4.812 -0.639 (-1.283, 0.041) 
           
PHQ-9 1: Baseline 19.241 4.639 20.814 4.843 4.742 -1.572 -0.332 (-0.832, 0.187) 
 2: 3 months 12.586 6.222 16.242 7.071 6.652 -3.656 -0.550 (-1.082, 0.014) 
 3: 6 months  10.352 7.465 14.966 6.353 6.955 -4.614 -0.663 (-1.226, -0.064) 
 4: 9 months 9.602 6.440 14.610 8.132 7.127 -5.008 -0.703 (-1.346, -0.020) 
 5: 12 months 9.350 6.712 14.510 7.816 7.206 -5.161 -0.716 (-1.365, -0.027) 
 6: 18 months 9.265 7.291 14.483 7.644 7.449 -5.217 -0.700 (-1.357, -0.005) 
 
†Effect size computed using estimated marginal means, and the SD of the outcome variable from the observed data at the respective 
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Figure 2: HAM-D and PHQ outcomes - estimated marginal means from exponential decay model with 
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Table 4. Incremental Cost-effectiveness Ratios 
 
  





Reference Case Analysis (QALY at 18 months) 
CMHT $5,177.60 -$503.43A 0.87 0.03A Dominant 
(ISTDP) 
ISTDP $4,674.17  0.90   
Secondary Analysis (HAM-D at 18 months) 
CMHT $5,177.60 -$503.43A 8.569 -2.04A Dominant 
(ISTDP) 
ISTDP $4,674.17  6.529   
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